BIO-PREDISC-TIA SWISS Cohort Study
- Conditions
- Cerebrovascular Disease, Ischemic Stroke
- Registration Number
- NCT03994003
- Lead Sponsor
- Dr. med. Carlo Cereda
- Brief Summary
This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
-
Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting <24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.
- At least 18 years old.
- Having given their Informed Consent.
-
· Patients with ocular TIA (Amaurosis fugax).
- Patients that still have neurological deficits at the moment of inclusion.
- Contraindication to perform MRI.
- For women: pregnancy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA. 1 year Diagnostic performance according to PREDISC scale
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Ospedale Regionale di Lugano
🇨🇭Lugano, Ticino, Switzerland
Centre hospitalier Vaudois
🇨🇭Lausanne, Vaud, Switzerland